A phase 3 randomised controlled study of Cabozantinib (XL184) vs Everolimus in subjects with metastatic renal cell carcinoma that has progressed after prior VEGFR tyrosine kinase inhibitor therapy

Project: Research

StatusFinished
Effective start/end date1/09/1330/05/15